FGFR2 and ameloblastoma: Promising candidates for molecular targeted therapy in ameloblastoma include vemurafenib and dabrafenib to target mutated BRAF, trametinib for MEK mutations, and ponatinib and regorafenib for FGFR2 mutations; vemurafenib and dabrafenib for BRAF and trametinib for MEK were three molecular targeted therapies for BRAF V600E mutations sanctioned by the US Food and Drug Administration (30).